Supernus Pharmaceuticals (SUPN) Common Equity (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 4.47% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 4.47% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 2.51% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• Over the last five years, Common Equity for SUPN reached as high as $1.1 billion in Q1 2026 and fell as low as $828.4 million in Q1 2022.
• Historically, Common Equity has averaged $958.1 million across 5 years, with a median of $929.2 million in 2024.
• On a YoY basis, Common Equity climbed as much as 12.39% in 2024 and fell as far as 1.87% in 2024.
• Year by year, Common Equity stood at $886.2 million in 2022, then rose by 3.98% to $921.5 million in 2023, then increased by 12.39% to $1.0 billion in 2024, then rose by 2.51% to $1.1 billion in 2025, then increased by 1.42% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.